Prostate Cancer

Latest News


Latest Videos


CME Content


More News

An in-depth discussion regarding experience treating nonmetastatic castration-resistant prostate cancer (CRPC) with apalutamide, enzalutamide, and darolutamide, and factors that impact treatment selection.

An overview of drug approvals for nonmetastatic castration-resistant prostate cancer (CRPC), and discussion regarding the potential utility of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) to guide treatment decisions.